About the Study: Positive 12-month TPIP results reported Evaluated treatment in PAH patients Supports long-term clinical development Key Highlights: Positive long-term clinical outcomes Advances pulmonary hypertension research Strengthens rare disease pipeline "Congratulations to the Insmed Incorporated team on these encouraging clinical results." Will Lewis, Adele Deering, Christie Camelio, Eugene Sullivan, Kevin Mange, MD, MSCE, Martina Flammer, MD, MBA Long-term clinical evidence continues to drive innovation for patients with rare pulmonary diseases. #Insmed #TPIP #PAH #RareDisease #ClinicalTrials #Biopharma #HealthcareInnovation FDA The National Institutes of Health Centers for Disease Control and Prevention ISO - International Organization for Standardization World Health Organization European Medicines Agency Pulmonary Hypertension Association European Society of Cardiology American Heart Association American College of Cardiology American Thoracic Society European Respiratory Society World Heart Federation || cGxP.wire || cGxP.Directory || cGxP.jobs || cGxP.Tech || To view or add a comment, sign in "Alcoholic Risks Surge Past One Drink" New York Times, June 16,2026 If you have a Self-Directed IRA or SOLO 401K You can now invest in Life Science Venture Capital
Who Should NOT Drink Oatzempic Some patients should not drink Oatzempic including: Patients in the early stages of recovery People with active reflux or acid reflux Gastric bypass patients who are prone to dumping syndrome Diabetic patients who are taking insulin Patients who are taking GLP-1 medications People who are using it as a meal replacement People who have a history of eating If you are thinking about trying Oatzempic you should talk to your doctor first
GLP-1 compounds are different
These particles interfere with the signals sent to your brain about head movements, leading to the sensation of spinning or tilting
